SHELTON, CT / ACCESS Newswire / June 15, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader...
Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1...
COPENHAGEN, Denmark, June 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its...
Two of the world's most experienced emergency responders, the Uganda Red Cross Society and Doctors Without Borders, will each receive...
Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy Paris, June 10, 2026. Sanofi today...
SOUTH SAN FRANCISCO, Calif., June 09, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a...
82% of subjects achieved an MCID in their MG-ADL with a mean >4 point improvement in MG-ADL observed in Phase...
LIBERTY clinical trial will evaluate the comparative safety and tolerability of VYD2311 versus mRNA COVID-19 vaccine, as well as explore...
WestGene’s established targeted LNP platform combined with Cartesian’s mRNA payload from Descartes-08 integrates two independently, clinically tested technologies for rapid...
COPENHAGEN, Denmark, June 9, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced the award of a government contract valued...
Lynch syndrome is an inherited condition affecting 1 in 300 people that causes lifetime cancer risk of up to 80%The...
SHELTON, CT / ACCESS Newswire / June 8, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader...
Advanced analytical services support partners from product characterization and assay development to GMP readiness and clinical manufacturingIntravacc offers state-of-the-art analytical...
Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target...
Deepening Engagement with the Global Biopharmaceutical Community Auckland, New Zealand, June 05, 2026 (GLOBE NEWSWIRE) -- WORK Medical Technology Group...
Video segment examines current Ebola outbreak concerns, unmet need surrounding the Bundibugyo strain and Ampligen’s previously published antiviral research Discussion...
FT819 off-the-shelf CAR T-cell therapy product candidate continues to broaden patient access with 21 SLE patients now treated, including as...
Includes up-front issuance of preferred stock for $2.5 million and secured promissory notes for $7.72 million Uniquely structured, flexible financing supports...
Hangzhou, China, June 03, 2026 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical”, the “Company” or...
AUSTIN, Texas, June 03, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: With oncology drug-development expenses continuing to rise and regulatory...